Intestinal Rehabilitation Episode 5, Literature Review

Published: 2022-12-01

1 Views

0 Likes

0 Shares

0 Comments

StayCurrentMD

View profile →

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

Ellen Ancisco — host
Paul Wales — guest
Michael Helmrath — guest
Cecilia Jigena — host

Chapters

0:04Introduction and Episode Overview — Hosts introduce the fifth episode in the intestinal rehabilitation series, featuring Drs. Paul Wales and Michael Helmrath from Cincinnati Children's Hospital. The episode will review two papers on medical management of intestinal failure.
1:43Teduglutide Phase 3 Trial Results — Discussion of a 24-week study on teduglutide (GLP-2 analog) showing 69% of patients on 0.05 mg/kg dose achieved 20% TPN reduction and 10% discontinued TPN. Patient selection criteria and the requirement for enteral stimulation are explained.
4:29Mechanism of Action and Clinical Application — Explanation of how GLP-2 analogs improve fluid and electrolyte management at the epithelial layer despite receptors not being on enterocytes. Discussion of timing for therapy introduction and the importance of early intervention.
7:17Broader Implications and Summary — Discussion of how understanding fluid and electrolyte management benefits populations beyond intestinal failure patients. Emphasis on multidisciplinary team approach and episode wrap-up.

Key claims

1:48GLP-2 analog is the only trophic peptide currently approved for children — Paul Wales
1:58Teduglutide is a GLP-2 analog with brand names Gattex and Rebusto — Cecilia Jigena
2:06GLP-2 is produced and released by enteroendocrine cells in the distal ileum and right colon — Paul Wales
2:15GLP-2 has a stimulatory effect on the GI tract — Paul Wales
2:30The trial was a 24-week study following a prior 12-week Carter paper — Paul Wales
2:48Two doses were studied: 0.025 mg/kg and 0.05 mg/kg compared to standard of care — Ellen Ancisco
2:59Both doses showed benefit, but 0.05 mg/kg showed greater benefit — Paul Wales
3:04At 0.05 mg/kg dose, 69% of patients achieved 20% reduction in TPN support — Paul Wales
3:0410% of children total discontinued TPN — Paul Wales
3:19A more recent paper from Spain showed even more optimistic real-life results — Paul Wales
3:31Patient selection requires medical stability — Paul Wales
3:34Therapy requires more frequent visits and assessments — Paul Wales
3:52Adaptation is driven by trophic peptides in conjunction with enteral stimulation — Paul Wales
4:17The gut needs something to absorb for the drug to work; TPN should be supplementation not total nutrition — Ellen Ancisco
4:29Fluid management presents the greatest challenge in these patients — Michael Helmrath
4:29Teduglutide helps control fluid management — Michael Helmrath
4:45GLP-2 receptors are not on the enterocyte — Michael Helmrath
4:58Secretory effects of short bowel resulting in high fluid secretions are improved at the epithelial layer — Michael Helmrath
5:11GLP-2 analogs work by helping to reclaim fluid that results from feeds — Cecilia Jigena
5:18Patients who benefit most are those whose limiting factor is fluid and electrolyte management — Cecilia Jigena
6:26There are at least 20 different types of enteroendocrine cells — Michael Helmrath
6:35Fluid regulation inside cells relates to electrochemical shifts from transporters like CFTR — Michael Helmrath
6:44Nutrient absorption transporters are regulated by hormones like peptide YY — Ellen Ancisco
7:01Therapy should be introduced sooner than later but not blindly — Michael Helmrath
7:36The number one cause of death of children in the world is fluid losses from diarrhea and malnutrition — Michael Helmrath
7:45Understanding fluid and electrolytes will benefit a wider population than just intestinal failure patients — Michael Helmrath

Open questions

How to utilize peptide hormones in synergy with other therapies for better outcomes in the next decade
Optimal timing for introducing GLP-2 analog therapy to maximize benefit during intestinal growth and development
Whether patients who are 100% PN dependent can benefit from teduglutide therapy

This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.

GLP-2 Analog Therapy in Pediatric Intestinal Failure: Selection and Mechanism

The episode's teaching points arranged as a structured lesson, building from the basics up to the finer points. Written by Kai from the episode transcript and reviewed before publishing.

Teaching arc · AI-written, human-reviewed

This discussion unpacks when and how teduglutide works in children with intestinal failure, moving from patient selection through mechanism to the clinical challenge the drug actually solves.

Adaptation requires both enteral stimulation and hormonal amplification. Feeding turns on the adaptation process — that is the light switch 3:52. But trophic peptides like GLP-2 control the intensity of that adaptation, gradually turning the light up or down [q2]. A child on 100% parenteral nutrition has the switch in the off position; teduglutide cannot amplify a signal that is not present. The gut needs something to absorb for the drug to work 4:17. This is why patient selection begins with ensuring some enteral intake exists, even if TPN remains the dominant source of nutrition.

The ideal candidate is medically stable with fluid-electrolyte limitation as the primary barrier. Medical stability is the first gate 3:31. The second is recognizing what actually limits the patient's progress. Children who benefit most are those whose primary problem is reclaiming the fluid that results from feeds, not those with complete malabsorption 5:18. At the 0.05 mg/kg dose, 69% of patients achieved a 20% reduction in TPN support 3:04, but the endpoint reflects fluid and electrolyte control more than caloric independence. Fluid management presents the greatest challenge in these patients 4:29, and teduglutide helps control that 4:29 [q3].

The mechanism is indirect but clinically potent. GLP-2 receptors are not located on the enterocyte 4:45, yet the drug improves secretory effects at the epithelial layer 4:58. It works by helping to reclaim fluid from feeds 5:11, addressing the high-output secretory state that defines short bowel syndrome. This is not intuitive — the hormone does not act where you would expect it to — but the clinical effect is reproducible. Understanding this mechanism clarifies why the drug works best in patients whose limiting factor is fluid loss rather than nutrient absorption failure.

Timing matters: introduce therapy early enough to capitalize on growth. The intestine grows and develops most actively early in life. Therapy should be introduced sooner than later, but not blindly 7:01. The strategy is to use GLP-2 analogs to achieve fluid control early, enabling better enteral nutrition, which in turn supports gut growth during the window when adaptation potential is highest. Delaying until a child is older and medically complicated wastes that window. But starting without ensuring enteral stimulation is present wastes the drug.

This is a problem with implications beyond intestinal failure. The number one cause of death in children worldwide is fluid losses from diarrhea and malnutrition 7:36. Understanding fluid and electrolyte regulation at the epithelial level — how enteroendocrine cells, transporters like CFTR, and hormones like peptide YY interact 6:35 6:44 — will benefit a far wider population than the small cohort with intestinal failure 7:45. The lesson here is not just about when to start teduglutide. It is about recognizing that fluid reclamation, not caloric absorption, often determines whether a child can advance enterally, and that hormonal modulation of that process is now a tool we can deploy systematically rather than waiting passively for adaptation to occur.

This episode is part of a series — read the series guide: Intestinal Rehabilitation: From Crisis Management to Lifelong Care

Topic overview

Two pediatric surgeons from Cincinnati Children's Hospital discuss pharmacologic therapy for intestinal failure, focusing on teduglutide (a GLP-2 analog). In a 24-week phase 3 trial, 69% of patients on the 0.05 mg/kg dose achieved a 20% reduction in parenteral nutrition support, and 10% discontinued TPN entirely. The drug works by improving fluid and electrolyte management at the epithelial layer, though enteral stimulation through feeding is required for adaptation to occur. Patient selection requires medical stability and families prepared for frequent monitoring, with optimal candidates being those whose limiting factor is fluid and electrolyte management rather than complete inability to absorb nutrients.

Keywords

intestinal failure short bowel syndrome secretory diarrhea malnutrition teduglutide Gattex Rebusto GLP-2 analog peptide YY Cincinnati Children's Hospital

Hashtags

#IntestinalRehabilitation #ShortBowelSyndrome #PediatricSurgery #TPN

Transcript

Click "Show Transcript" to view the full text (8940 characters)

Hi everyone. Welcome back. This is a stay current podcast. This week we're coming back with another installment in our series with intestinal rehabilitation. Again, we're talking to two of the experts in intestinal rehabilitation from Cincinnati Children's Hospital. We have Dr. Paul Wales, the current surgical director. I'm Paul Wales. I'm a pediatric surgeon here at Cincinnati Children's Hospital, and Dr. Michael Helmrath, the prior surgical director. I'm Michael Helmrath. I'm a pediatric surgeon also doing intestinal. Your surgery and research here at Cincinnati Children. I'm Ellen Ancisco. I'm Cecilia Jigena, and we're with the stay current team. And so this week we're kind of doing a journal club here. We're going to talk about two articles, and really they're related to medical treatment for intestinal rehab. One of the article is about a GLP-2 analog, and the second paper talks about the enter endocrine cells and the peptides that secrete that helps manage the fluids and Electrolytes to help absorb nutrients in these patients. OK, so we'll dive into the first article. It's called Safety and Efficacy of taglutide in Pediatric Patients with Intestinal failure Due to Short Bowel syndrome, a 24 week phase 3 study, and Dr. Wales is actually an author on this paper. It was published in the Journal of Parenteral Enteral Nutrition back in May of 2020. The papers that we talk about are linked below so you can take a look for yourself. Dr. Wales started out by telling us why this research is important. One of the tools that intestinal rehab programs have is pharmacologic therapy. One category of therapies are the trophic peptides, and the only trophic peptide that is currently approved for children is GLP-2 analog. And GLP-2 analog is called tedulutide. Gattex is one of the brand names, and Rebusto is what they. in Canada and some other places, GLP-2 is produced and released by the enteroendocrine cells in the distal ileum in the right colon. It has a stimulatory effect on the GI tract. Depending on your anatomical subtype, you have a better capacity to produce enough GLP-2 to become independent of parenteral support. Let's talk about the paper. The trial that is in the paper that we're presenting was a 24 week study which Follows the Carter paper, which was a 12-week study. And so basically this study was looking at a couple of different doses of taglutide, and in this paper two doses were used. So we had either 0.025 mg per kilogram or 0.05 mg per kilogram of taglutide compared to the standard of care, i.e., not receiving taglutide. Both showed benefit, but the 0.05 dose showed a greater benefit. And And what happened to these patients? At the 0.05 dose, 69% of patients achieved the endpoint of the trial, which was a 20% reduction in TPN support, and 10% of kids total got off TPN. And, and then the more recent paper out of Spain, which was like a real-life experience, showed even more sort of optimistic results. which patients can actually benefit from this. You want to select patients that are medically stable. And the other consideration here is you need a family that realizes that when you start this therapy, it's going to require more frequent visits and assessments, so a kid who's 100% PN dependent. Can they go on Gads? In case you forgot, that was Doctor Michael Holmbraath. You know, if we think about adaptation, what drives adaptation is, you know, trophic peptides is one of the parts of, of the process, but that's usually in conjunction with enteral stimulation. That's an important concept that's hard to teach. The fact that the light switch. is turned on by feeding, but the, the amount of light in the room is gradually turned up or down based on the hormones that are augmented by GLP-2. That's another great point that you have to, even if these kids, you know, need TPN, they need it as supplementation, not for their total nutrition. There has to be something for the gut to absorb in order for the drug to work. Nutrition is key to growing and developing them. But the management of the fluids really presents us with the greatest challenge, and that's been one of my my impressions that this medicine really helps us start to control that. So I think it's important to talk about mechanism. You alluded to the fact that the receptors for GLP-2 are not on the enterocyte, and yet what we're seeing clinically is. That the secretory effects of short bowel that result in the high fluid secretions that challenge all of us are improved at the epithelial layer. So to explain this. What he's saying is that TLP2 analogs work by helping to reclaim the fluid that results from feeds. And so the patients that will benefit more from this are those who are in the situation whereby the limiting factors to moving ahead are the fluid and electrolytes management. And so the challenges for the next decade, I think, involve these peptide hormones. How to utilize them in synergy with therapies that are going to give us the better outcomes. OK, so that was our first paper. Let's see what we have next. And this paper that Dr. Holmrath is an author of is called Enteroendocrine Cells Couple Nutrient Sensing to Nutrient Absorption by Regulating Ion Transport, and this was published in Nature Communications also back in 2020. Studies like this that allow us to study specific human conditions that can't be mimicked in animal. Models give us insight into understanding the nutrient sensing that we need to understand in managing these patients and probably more broadly patients with secretory diarrhea and other conditions. Endocrine cells actually there's many different subtypes. We know at least 20 different types of, uh, endocrine cells that exist in there. What regulates the, the fluid inside the cell. To do with the electrochemical shifts that occur from transporters like CFTR. Right, he's talking a lot about kind of the underlying biology for why all of this works, why all this is important, and so he's saying that these transporters that are a key part of nutrient absorption, they are regulated by these hormones like peptide YY. But the natural history of this. is to understand the progression that happens early in life that you want to take advantage of in the intestine growing and developing and the strategy of when to introduce these things, as Paul was saying, should be sooner than later, but not just blindly done. And we need to like have good nutrition in order for the gut to grow, and so I think what he's saying, we have to, you know, treat the kids early enough that they have the benefit. Of these GLP-2 analogs so that they can be well nourished, grow, and in the future, ideally not have this problem. I would remind people that the number one cause of death of children in the world is fluid losses from diarrhea, malnutrition, and other, other conditions. So understanding just fluid and electrolytes and how to grow healthy is going to benefit a wider population. By far than what we think about with intestinal failure, and as a surgeon, you have to be part of the team. Again, I feel like we in this podcast series, we are always talking about nutrition. We're always also talking about how important multidisciplinary teams, so we need teamwork of peptides and hormones. We also need the teamwork of practitioners, gastroenterologists, nutritionists, dietitians, surgeons. The list goes on OK, so, it's a pretty dense discussion we've had during today. How would you summarize it, Cecilia? OK, so I will summarize it by saying that we have a lot of peptides that the enteroendocrine cells secrete that help with the absorption of nutrients in the gut. And then we have this GLP2 analog that can help our patients with the fluid and electrolyte management. So these patients that have problems with enteral nutrition because they can't manage their fluids will benefit from this drug and really, you know, we talked about a couple of papers here, one, a more clinical application of GLP-2 analogs and how using them in patients who can actually decrease their needs for TPN and maybe even get off of TPN. And then another one kind of talking about the underlying biology with Dr. Helmrath, you know, one of the key issues is, is really their absorption of nutrients in the gut and so enhancing that, optimizing that. This turned out to be really key for these kids with intestinal failure. We'll see what comes next. Yeah, perfect. Stay tuned for more episodes like this. We're gonna continue having conversations with Doctor Wales and Doctor Helm Roth. If you liked what you heard, don't forget. Leave us a rating or review on Apple Podcasts or Spotify, wherever you're listening. Don't forget to subscribe to our YouTube channel and download the Stay Current in Pediatric Surgery app. It has all these podcasts, videos, a lot more. Until next time, I'm Ellen and Cisco, and I'm Cecilia Geno. This is the Stay Current podcast.

Comments

Loading comments...